Osrodek Badan Klinicznych Clinsante s.c. Ewa Galczak-Nowak Malgorzata Trzaska

At Osrodek Badan Klinicznych Clinsante s.c. Ewa Galczak-Nowak Malgorzata Trzaska in Torun, cardiovascular research focuses on atherosclerotic cardiovascular disease and heart failure, with studies also addressing kidney-related complications in people with complex cardiac conditions. The trials are designed to test new treatment options and better understand how to reduce serious heart and vascular events.

• Preventing major adverse cardiovascular events in people with high-risk or established ASCVD
• Evaluating therapies for heart failure with impaired kidney function
• Studying approaches to lower the risk of cardiovascular death, stroke, and urgent revascularization

These studies aim to improve long-term outcomes for patients at risk of major cardiovascular complications.

Respiratory research at this site centers on chronic obstructive pulmonary disease, with attention to how treatment can improve breathing-related health and broader cardiopulmonary outcomes. The work is aimed at assessing whether newer treatment combinations can provide better control of COPD and lower the chance of severe complications.

• Testing treatment strategies for COPD
• Evaluating effects on severe cardiopulmonary outcomes
• Comparing combination therapies to improve disease control

This research reflects a strong interest in finding more effective ways to manage chronic lung disease and its impact on overall health.

The site also conducts clinical trials in mental disorders, especially major depressive disorder and depression with significant anhedonia. These studies are exploring new adjunctive treatments to improve symptoms, while also looking at safety and tolerability over longer periods.

• Improving depressive symptoms in MDD with moderate-to-severe anhedonia
• Assessing long-term safety of new adjunctive depression treatments
• Testing therapies for patients who have not responded well to current antidepressants

There is also research relevant to Alzheimer’s disease, reflecting broader interest in cognition, functioning, and quality of life in neuropsychiatric care.